Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(617)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
- July 2009
- Teaching Note
Khosla Ventures: Biofuels Strategy (TN)
Teaching Note for [809004]. View Details
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Biotechnology Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Biotechnology Industry; Biotechnology Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Biotechnology Industry; Biotechnology Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 22 Nov 2016
- First Look
November 22, 2016
commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details
Keywords: Sean Silverthorne
- Research Summary
Overview
By: Kyle R. Myers
Professor Myers studies the economics of what determines the rate and direction of innovation. He has examined the reallocation of scientists through the use of targeted research grants at the National Institutes of Health, and is working to further understand how... View Details
Keywords: Technology Networks; Commercialization; Science-Based Business; Research and Development; Knowledge Management; Patents; Innovation Strategy; Technological Innovation; Health Care and Treatment; Entrepreneurship; Health; Innovation and Invention; Science; Technology; Knowledge; Intellectual Property; Economics; Microeconomics; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
- 01 Feb 1999
- News
Classmates Rally to Help Family Stricken with Rare Disease
scientists and researchers, in conjunction with several biotechnology companies, including Genzyme Corp., are now ready to test on humans an enzyme replacement therapy that has been successful in reversing the disease in laboratory... View Details
- 31 Aug 2010
- First Look
First Look: August 31
a national sample of 6,000 life scientists whose careers span more than 20 years. We find sharp gender differences in participation in for-profit ventures, which we measure as the likelihood of joining the scientific advisory board (SAB) of a View Details
Keywords: Sean Silverthorne
- September 2012 (Revised January 2014)
- Case
Aqua Bounty
By: Lucy White and Stephen Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details
Keywords: IPO; Valuation; Real Options; Decision Tree; Biotech; Genetically Modified; Salmon; Entrepreneurship; Finance; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; South America
White, Lucy, and Stephen Burn-Murdoch. "Aqua Bounty." Harvard Business School Case 213-047, September 2012. (Revised January 2014.)
- September 2000
- Case
Novartis Agricultural Discovery Institute (A)
Steve Briggs, a PhD biologist, is asked to propose a strategy to take global life-science giant Novartis into the rapidly expanding field of plant genomics. View Details
Keywords: Design; Plant-Based Agribusiness; Genetics; Infrastructure; Biotechnology Industry; Biotechnology Industry
West, Jonathan, and Christian G. Kasper. "Novartis Agricultural Discovery Institute (A)." Harvard Business School Case 601-010, September 2000.
- April 1998 (Revised June 1998)
- Supplement
Pioneer Hi-Bred International, Inc.: Supply Management (Addendum)
By: Francis Aguilar, Paul Clark and Xin Xi He
Addendum to case. View Details
Aguilar, Francis, Paul Clark, and Xin Xi He. "Pioneer Hi-Bred International, Inc.: Supply Management (Addendum)." Harvard Business School Supplement 898-239, April 1998. (Revised June 1998.)
- October 1998 (Revised December 1999)
- Case
Gene Research, the Mapping of Life and the Global Economy
By: Ray A. Goldberg and Juan Enriquez-Cabot
A new firm is being created to speed up the process of mapping humans, animals, and plants by combining gene technology with rapid gene identification to improve the health and well being of the human population and the productivity of crops and animals. How does one... View Details
Keywords: Information Technology; Organizational Structure; Technological Innovation; Business Processes; Health Care and Treatment; Performance Productivity; Welfare; Agribusiness; Genetics; Science-Based Business; Biotechnology Industry; Biotechnology Industry
Goldberg, Ray A., and Juan Enriquez-Cabot. "Gene Research, the Mapping of Life and the Global Economy." Harvard Business School Case 599-016, October 1998. (Revised December 1999.)
- 15 Dec 2020
- Blog Post
MBA Voices Blog: A Year in Review
decision maker. Read More 4 Things to Know About the MS/MBA Biotech “I was initially attracted to Harvard’s MS/MBA Biotechnology: Life Sciences program because of the emphasis on ethical decision making, and ultimately chose the program with the goal of becoming an... View Details
- 06 Sep 2024
- Blog Post
Harvard Business School Announces 2024 Goldsmith Fellows
noted, “I’m excited to learn from other fellows and explore opportunities for collaboration across other systems, including policy, healthcare, and criminal justice.” Keemia Azvine. Keemia, who is pursuing a MS/MBA in Biotechnology Life... View Details
- July 2014 (Revised January 2017)
- Course Overview Note
Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus
This Course Outline and Syllabus gives an overview of the Spring 2016 class Building Life Science Businesses.7 View Details
Keywords: Healthcare Ventures; Entrepreneurial Management; Entrepreneurship; Entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Asia; North America; Europe
Hamermesh, Richard G. "Building Life Science Businesses Spring Term 2017: Course Outline and Syllabus." Harvard Business School Course Overview Note 815-003, July 2014. (Revised January 2017.)